| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Technical Briefs |
1 Laboratoire de Virologie and7
Service d’Urologie, Hôpital Lapeyronie, Montpellier, France;
2 INSERM U475, Immunopathologie des Maladies Tumorales et Autoimmunes, Montpellier, France;
3 Service d’Urologie, Clinique Beau-Soleil, Montpellier, France;
4 Laboratoire de Biologie Cellulaire and6
Departement d’Information Médicale, Hôpital Arnaud de Villeneuve, Montpellier, France;
5 INSERM U540, Endocrinologie Moléculaire et Cellulaire des Cancers, Montpellier, France;
8 UMR 2714 bioMerieux/CNRS, IFR 128 BioSciences Lyon-Gerland, Lyon, France;
aaddress correspondence to this author at: Laboratoire de Virologie, Hôpital Lapeyronie, 291 Avenue du Doyen Giraud, 34295 Montpellier, France; fax 330-467-338-334, e-mail jp-vendrell@chu-montpellier.fr
| The first 300 words of the full text of this article appear below. |
The detection of circulating tumor cells in blood (1)(2)(3)(4) requires highly sensitive, specific, and reproducible methods. During the last decade, immunocytochemistry (5)(6), reverse transcription-PCR (7)(8)(9), flow cytometry (10)(11)(12)(13), and CellSearch and CellSpotter systems (14) have been assessed for the early detection of these rare circulating cells to predict tumor progression, survival in patients with metastatic cancer, and tumor dormancy (15). The enzyme-linked immunosorbent spot (ELISPOT) assay has been validated for enumeration of cells secreting immunoglobulins and antibodies (16)(17), cytokines (18), and viral antigens (19). The 2-color ELISPOT assays allow enumeration of cells simultaneously secreting 2 cytokines (20)(21), IgG or IgA (22), or monoclonal immunoglobulins into the blood of patients with multiple myeloma (23) and MUC-1/Cath-D–secreting cells in metastatic breast cancer patients (24).
Here we describe a new ELISPOT assay for detection of human prostate-specific antigen (PSA)–secreting cells (SCs) in patients with prostatic carcinoma (PCa). This test was developed and optimized by use of LNCaP (ATCC; CRL-1740) and PC-3 (ATCC CRL-1435; provided by Pr. Pantel, Tumor Biology Institute, Hamburg, Germany) cell lines, which do and do not secrete PSA, respectively (25); PSA-SCs were then assessed in the blood of 114 men who had given written informed consent. The patients were divided into 4 groups: (a) 24 patients (median age, 73.5 years; range, 58–90 years) diagnosed with clinically localized PCa (LPCa), (b) 24 patients with metastatic PCa (MPCa), (c) 31 patients with benign prostatic hyperplasia (BPH; n = 27; median age, 69 years; range, 52–82 years) or acute prostatitis (AP; n =
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  H. Schwarzenbach, C. Alix-Panabieres, I. Muller, N. Letang, J.-P. Vendrell, X. Rebillard, and K. Pantel Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer Clin. Cancer Res., February 1, 2009; 15(3): 1032 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Alix-Panabieres and K. Pantel EPISPOT Assay: Detection of Proteins Secreted by Viable Disseminating Tumor Cells in Solid Tumor Patients Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 611 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Shaffer, M. A. Leversha, D. C. Danila, O. Lin, R. Gonzalez-Espinoza, B. Gu, A. Anand, K. Smith, P. Maslak, G. V. Doyle, et al. Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2023 - 2029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Alix-Panabieres, J.-P. Vendrell, O. Pelle, X. Rebillard, S. Riethdorf, V. Muller, M. Fabbro, and K. Pantel Detection and Characterization of Putative Metastatic Precursor Cells in Cancer Patients Clin. Chem., March 1, 2007; 53(3): 537 - 539. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
